Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWVoriconazole is a triazole antifungal agent and a derivative of fluconazole (Item No. 11594).1,2 It is active against a variety of yeast and fungi, including clinical isolates of A. flavus, A. fumigatus, F. oxysporum, F. solani, C. albicans, and C. neoformans (MICs = <0.03-16 µg/ml).1 Voriconazole is also active against 56 clinical isolates of fluconazole-resistant C. albicans (MICs = 0.015-8 µg/ml).2 It inhibits ergosterol biosynthesis in C. albicans, C. glabrata, A. fumigatus, and A. flavus (IC50s = 0.03-1 µg/ml).3 Voriconazole (10 mg/kg twice per day, i.v.) decreases the number of lung colony-forming units (CFUs), reduces alveolar collapse and lung inflammatory cell infiltration and necrosis, and increases survival in a rat model of invasive pulmonary aspergillosis.4 Formulations containing voriconazole have been used in the treatment of fungal infections.
WARNING This product is not for human or veterinary use.
1. In vitro activity of the new triazole voriconazole (UK-
2. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-
3. Posaconazole is a potent inhibitor of sterol 14α-
4. Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species. Mycopathologia 177(1-2), 11-18 (2014).